Condition
Paranasal Sinus Neoplasms
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Completed3
Recruiting1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06940180Phase 2Recruiting
Toripalimab With Chemotherapy for Sinus Cancer
NCT00117572Phase 3Completed
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
NCT00462735Phase 2Completed
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
NCT00970502Phase 1Completed
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
NCT00347256Not ApplicableWithdrawnPrimary
Chemoradiotherapy Followed by Surgery for Advanced Paranasal Sinus Cancer
Showing all 5 trials